Targeting SARS-CoV-2 Mpro and PLpro by Repurposing Clinically Approved Drugs
Qiaoyu Fang, Meng Lu, Derong Chen, Liangxu Xie, Wenxu Hong, Zhang Zhang, Xuqiao Hu, Daniele Focosi · 2025
Read Targeting SARS-CoV-2 Mpro and PLpro by Repurposing Clinically Approved Drugs by Qiaoyu Fang, Meng Lu, Derong Chen, Liangxu Xie, Wenxu Hong, Zhang Zhang, Xuqiao Hu, Daniele Focosi (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12737678.txt.
Description
Qiaoyu Fang and co-authors screen approved drugs against two viral enzymes of SARS-CoV-2 in a paper from two thousand twenty-five. The enzymes, Mpro and PLpro, drive virus copying and blunt host defenses. Blocking them could slow infection, and old drugs offer a fast track.
Using chip screening, enzyme tests, a fake-virus assay, and computer docking, the team found two standouts: oxytocin and risedronate sodium. Both shifted the enzymes' activity and kept the virus from copying in the tests. The authors say these drugs, and cephalosporins as a class, widen the library of candidates for coronavirus care. More study is needed before any clinical use.
Catalog record
| CREATOR | Qiaoyu Fang, Meng Lu, Derong Chen, Liangxu Xie, Wenxu Hong, Zhang Zhang, Xuqiao Hu, Daniele Focosi |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |